
At PHARMA point 2026 in Thessaloniki on 10–11 October, pharmacy representatives linked medicine shortages in Greece to parallel exports and called for tighter controls. These[…]

On 12 May 2026 the European Parliament and the Council reached a provisional agreement on the Critical Medicines Act. EMA welcomed it as a step[…]

The reformed EU pharmaceutical legislation tightens obligations around shortages, while EMA is expanding the European Shortages Monitoring Platform. Companies should treat shortage management as a[…]

Under the reformed EU pharmaceutical legislation, Member States will be able to ask holders of products with market protection to place them on the national[…]

The reform of EU pharmaceutical law reshapes market exclusivity for orphan medicines. Published analyses of the final compromise describe a modulated system in place of[…]

One of the most closely watched parts of the EU pharmaceutical reform is how long innovators are protected from generic and biosimilar competition. Published legal[…]

The reform of EU pharmaceutical legislation has moved from negotiation to implementation planning. Published analyses report that the Council adopted the texts in autumn 2026,[…]

When PRAC reviewed immunoglobulin hypersensitivity reports in October 2026, batches of several products had already been withdrawn as a precaution in certain Member States. The[…]

PRAC has started a review of Deanxit (flupentixol/melitracen) after reports of movement disorders and memory and thinking problems, some of which persisted after treatment stopped.[…]

At its 26–29 October 2026 meeting, PRAC started a review of increased reports of hypersensitivity reactions with human normal immunoglobulin medicines, linked to specific batches.[…]